Hurricane Sandy Disrupts “The Disruptors”

Posted on Monday, October 29, 2012

At Real Endpoints, we know the importance of showing mothers respect – especially Mother Nature. It took a storm the magnitude of Sandy to disrupt “The Healthcare Disruptors”. But with a hurricane wrapped in...

Learn More

German Scoreboard: Payers 1, Pharma 1

Posted on Thursday, March 29, 2012

AstraZeneca and other biopharmas wait with bated breath for the first drug price tags to emerge from Germany’s new early added-benefit assessment process. So who’s winning as this...

Learn More

Is France Creating Its Own NICE?

Posted on Monday, March 26, 2012

Sort of. It seems that the French are getting more comfortable with the idea of calling health-economics by its real name, and of carrying out explicit cost-effectiveness evaluations a la NICE in the UK....

Learn More

The Healthcare Round-up: 2/7 -2/13

Posted on Tuesday, February 14, 2012

What’s better than a box of chocolates or a dozen fair trade, organic red roses? A #healthpolicyvalentine. It’s cheaper too. Wonks and journos quickly embraced the nerdy Twitter hash tag created last week by...

Learn More

Building The Greater Real Endpoints Community

Posted on Tuesday, January 17, 2012

  You know that old saw “it takes a village”? Before you roll your eyes, consider this: the same underlying premise embodied by this oft-uttered phrase is what’s driving the new...

Learn More

A Biosimilar Deal Making Bonanza

Posted on Thursday, January 5, 2012

Affordability matters to the branded drug industry just as much — if not more — than scientific innovation. Skeptical? Look no further than the trio of biosimilar deals in December 2011. On Dec....

Learn More

Happy Holidays From Real Endpoints

Posted on Friday, December 23, 2011

Real Endpoints will be on holiday until January 2, 2012. Wishing you and yours the very best this holiday season. Peace and joy in the New Year. Thanks for...

Learn More